Answers are grounded in this paper and cite their sources.
Crispr-based diagnostics improves detection of cancer using circulating cell-free DNA, suggesting enhanced precision oncology benefits.
Circulating cell-free DNA (cfDNA) has been established as a minimally invasive liquid biopsy biomarker with utility in the diagnosis of cancer, monitoring of treatment response, and detection of minimal residual...
No takes yet. Share an insight, caveat, or question.
Seth et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: